natgillin/translations-raw huggingface dataset:
If you are not sure about giving yourself the injection or you have any questions, please ask your doctor or nurse for help.
Če imate kakšna vprašanja o injiciranju zdravila, se za pomoč obrnite na svojega zdravnika ali medicinsko sestro.
Tell your doctor if you experience these symptoms.
Če se vam pojavijo ti simptomi,
Always keeping your skin pinched, depress the plunger slowly and evenly while grasping the finger flange until the entire dose has been given and the plunger cannot be depressed any further.
Kožo še najprej držite s palcem in kazalcem in bat počasi in enakomerno potisnite navzdol,
- The other ingredients are sodium acetate, sorbitol (E420), polysorbate 20 and water for injections.
- Pomožne snovi so natrijev acetat, sorbitol (E420), polisorbat 20 in voda za injekcije (glejte poglavje 2).
Musculoskelet al and connective tissue disorders
Bolezni mišično skeletnega sistema in vezivnega tkiva bolečina v kosteh mišično-skeletna bolečina
Pelgraz is for subcutaneous use.The injections should be given subcutaneously into the thigh, abdomen or upper arm.
Injekcije se morajo dati subkutano v stegno, trebuh ali zgornji del roke.
Pack size of one pre-filled syringe with one alcohol swab, in a blistered packaging.
Pakiranje z eno napolnjeno injekcijsko brizgo in enim alkoholnim zložencem v pretisnem omotu.
Package leaflet: Information for the user Pelgraz 6 mg solution for injection in pre-filled injector pegfilgrastim This medicine is subject to additional monitoring.
Navodilo za uporabo Pelgraz 6 mg raztopina za injiciranje v napolnjenem injektorju pegfilgrastim Za to zdravilo se izvaja dodatno spremljanje varnosti.
Pelgraz 6 mg solution for injection in pre-filled syringe Pelgraz 6 mg solution for injection in pre-filled injector
Pelgraz 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Pelgraz 6 mg raztopina za injiciranje v napolnjenem injektorju
White blood cell (WBC) counts of 100 x 109/L or greater have been observed in less than 1% of patients receiving pegfilgrastim.
Pri manj kot 1 % bolnikov, ki dobivajo pegfilgrastim, so opazili število belih krvničk, ki je enako 100 x 109/l ali večje.
Pelgraz 6 mg solution for injection in pre-filled injector Each pre-filled injector contains 6 mg of pegfilgrastim* in 0.6 mL solution for injection.
Pelgraz 6 mg raztopina za injiciranje v napolnjenem injektorju En napolnjen injektor vsebuje 6 mg pegfilgrastima* v 0,6 ml raztopine za injiciranje.
The usual dose is one 6 mg subcutaneous injection (injection under your skin) using a pre-filled injector and it should be given at least 24 hours after your last dose of chemotherapy at the end of each chemotherapy cycle.
(podkožna injekcija) z napolnjeno injekcijsko brizgo, ki jo morate prejeti vsaj 24 ur po zadnjem odmerku kemoterapije na koncu vsakega cikla kemoterapije.
Pelgraz 6 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 mL solution for injection.
Pelgraz 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima* v 0,6 ml raztopine za injiciranje.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (PRE-FILLED INJECTOR)
PODATKI NA ZUNANJI OVOJNINI ŠKATLA (NAPOLNJEN INJEKTOR)
Each pre-filled injector contains 6 mg of pegfilgrastim in 0.6 mL (10 mg/mL) solution for injection.
En napolnjen injektor vsebuje 6 mg pegfilgrastima v 0,6 ml (10 mg/ml) raztopine za injiciranje.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom
The incidence of hospitalisations and intravenous antiinfective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo (1% versus 14%, p < 0.001; and 2% versus 10%, p < 0.001).
kot med prejemnicami placeba (1 % v primerjavi s 14 %, p < 0,001, ter 2 % v primerjavi z 10 %, p < 0,001).
Package leaflet: Information for the user Pelgraz 6 mg solution for injection in pre-filled syringe pegfilgrastim This medicine is subject to additional monitoring.
Navodilo za uporabo Pelgraz 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi pegfilgrastim Za to zdravilo se izvaja dodatno spremljanje varnosti.
Pelgraz 6 mg solution for injection in pre-filled injector Before use, Pelgraz solution should be inspected visually for particulate matter.
Pelgraz 6 mg raztopina za injiciranje v napolnjenem injektorju Pred uporabo morate raztopino zdravila Pelgraz pregledati glede vidnih delcev.
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 mL (10 mg/mL) solution for injection.
Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml (10 mg/ml) raztopine za injiciranje.
Elevations in lactate dehydrogenase and alkaline phosphatase1;
Preiskave zvišanje laktatdehidrogenaze in alkalne fosfataze1, prehodno zvišanje jetrnih funkcijskih testov za ALT ali AST1
Additionally a higher incidence of febrile neutropenia was observed in younger children aged 0-5 years (75%) compared to older children aged 6-11 years and 12-21 years (70% and 33%, respectively) and adults (see sections 4.8 and 5.2).
(70 %) in 12 do 21 let (33 %) ter pri odraslih (glejte poglavji 4.8 in 5.2).
Injection site reactions, including injection site erythaema (uncommon) as well as injection site pain (common events) have occurred on initial or subsequent treatment with pegfilgrastim.
Med začetnim ali nadaljnjim zdravljenjem s pegfilgrastimom so se pojavile reakcije na mestu injiciranja, vključno z eritemom na mestu injiciranja (občasni) kot tudi bolečino na mestu injiciranja
How to store Pelgraz
Shranjevanje zdravila Pelgraz
Stevens-Johnson syndrome (SJS), which can be life-threatening or fatal, has been reported rarely in association with pegfilgrastim treatment.
V povezavi z zdravljenjem s pegfilgrastimom so redko poročali o Stevens-Johnsonovem sindromu
Pre-filled injector containing a pre-filled syringe (type I glass) with a permanently attached stainless steel injection needle.
Pelgraz 6 mg raztopina za injiciranje v napolnjenem injektorju Napolnjen injektor, ki vsebuje napolnjeno injekcijsko brizgo (iz stekla tipa I) s trajno pritrjeno nerjavečo jekleno injekcijsko iglo.
Pelgraz 6 mg solution for injection in pre-filled syringe Before use, Pelgraz solution should be inspected visually for particulate matter.
Pelgraz 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Pred uporabo morate raztopino zdravila Pelgraz pregledati glede vidnih delcev.
Pre-Injection
Pred injiciranjem
Each pre-filled syringe contains 0.6 mL of solution for injection.
Ena napolnjena injekcijska brizga vsebuje 0,6 ml raztopine za injiciranje.
Each pre-filled injector contains 6 mg of pegfilgrastim in 0.6 mL of solution.
En napolnjen injektor vsebuje 6 mg pegfilgrastima v 0,6 ml raztopine.
Keep the pre-filled injector in the outer carton in order to protect from light.
Napolnjen injektor shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Each pre-filled syringe injector contains 0.6 mL of solution for injection.
En napolnjen injektor z injekcijsko brizgo vsebuje 0,6 ml raztopine za injiciranje.
Pulmonary adverse reactions (interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis)
Bolezni dihal, prsnega koša in mediastinalnega prostora sindrom dihalne stiske pri odraslem2, pljučne neželene reakcije (intersticijska pljučnica, pljučni edem, pljučni infiltrati in pljučna fibroza), hemoptiza pljučna krvavitev
Pelgraz 6 mg solution for injection in pre-filled injector pegfilgrastim
Pelgraz 6 mg raztopina za injiciranje v napolnjenem injektorju pegfilgrastim
The safety and efficacy of Pelgraz have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g. nitrosoureas.
Pri bolnikih, ki dobivajo kemoterapijo, povezano z odloženo mielosupresijo, na primer nitrozouree, varnosti in učinkovitosti zdravila Pelgraz niso ovrednotili.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (PRE-FILLED SYRINGE)
PODATKI NA ZUNANJI OVOJNINI ŠKATLA (NAPOLNJENA INJEKCIJSKA BRIZGA)
Rare to
Redki 0 do
Keep the pre-filled injector in the carton in order to protect from light.
Napolnjen injektor shranjujte v škatli za zagotovitev zaščite pred svetlobo.
Unless your doctor directs you otherwise, you must stop breast-feeding if you use Pelgraz.
Če uporabljate zdravilo Pelgraz, morate prenehati dojiti, razen če vam zdravnik ne naroči drugače.
• bleeding from the lung (pulmonary haemorrhage)
• krvavitev iz pljuč.
Blood and lymphatic system disorders
Bolezni krvi in limfatičnega sistema trombocitopenija1 levkocitoza1
Haemoptysis
OVOJNINAH
Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further.
dokler ni injiciran celoten odmerek in dokler bat ni pritisnjen do konca.
Each pre-filled injector contains 0.6 mL of solution.
En napolnjen injektor vsebuje 0,6 ml raztopine.
• Push the handle straight down: The medicine will be injected as you push.
Zdravilo se bo injiciralo, medtem ko potiskate ročaj.
Pelgraz 6 mg solution for injection in pre-filled syringe pegfilgrastim
Pelgraz 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi pegfilgrastim
• Clean injection site: use an alcohol swab to wipe site clean.
Za čiščenje uporabite alkoholni zloženec.
Keep the syringe in the outer carton in order to protect from light.
Injekcijsko brizgo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
• Remove bottom cap: Twist and pull bottom cap to remove.
Da zamašek odstranite, ga obrnite in povlecite.
Mobilisation of PBPC
pegfilgrastima ANC
Stop using Pelgraz and seek medical attention immediately if you notice any of the symptoms described in section 4.
prenehajte uporabljati zdravilo Pelgraz in se nemudoma posvetujte z zdravnikom ali poiščite zdravniško pomoč.
Injection site reactions2
ki ne izvira od srca reakcije na mestu injiciranja2
Injecting Pelgraz yourself
Samoinjiciranje zdravila Pelgraz
• Dispose of the used Pelgraz pre-filled injector: Place injector in an approved sharps container.
• Odstranite uporabljen napolnjen injektor zdravila Pelgraz.
Allow to air dry.
Počakajte, da se mesto injiciranja posuši na zraku.
Sodium acetate* Sorbitol (E420) Polysorbate 20
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijev acetat* sorbitol (E420) polisorbat 20 voda za injekcije
- Keep this leaflet.
• Odstranite spodnji zamašek.
Do not try to inject yourself unless you have received special training from your doctor or nurse.
Če vas zdravnik ali medicinska sestra o tem nista posebej poučila, si ne poskušajte sami dajati injekcij.
Do not use if expiration date has passed.
Če je rok uporabnosti potekel, zdravila ne uporabljajte.
Keep the pre-filled syringe in the carton in order to protect from light.
Napolnjeno injekcijsko brizgo shranjujte v škatli za zagotovitev zaščite pred svetlobo.
Hypersensitivity reactions;
Bolezni imunskega sistema preobčutljivostne reakcije, anafilaksija
Lay the patient on their back.
Položite bolnika na hrbet.
2001/83/EC and any subsequent updates published on the European medicines web-portal.
Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
• If you use buprenorphine.
• Če uporabljate buprenorfin.
In some cases, further doses may be necessary.
V nekaterih primerih bodo potrebni dodatni odmerki.
Check for a response, to see if the person is conscious.
Preverite, ali se oseba odziva, da ugotovite stanje zavesti.
• If you take opioids to control pain.
• Če opioide jemljete za obvladovanje bolečine.
Can you feel breath on the cheek?
Ali na licu čutite sapo?
For 10 seconds check for breathing - is the chest moving?
10 sekund namenite preverjanju dihanja - ali se prsni koš dviga?
• Difficulty in sleeping.
• težave s spanjem
• Information about Nyxoid and the fact that it cannot replace provision of basic life support
• informacijo o zdravilu Nyxoid in dejstvu, da ne more nadomestiti nudenja osnovnih postopkov oživljanja
Tell your doctor if you have damage to the inside of your nose as this could affect how Nyxoid works.
Zdravniku povejte, če imate v nosu poškodbe, saj lahko to vpliva na delovanje zdravila Nyxoid.
In view of the indication and the broad therapeutic margin, overdose is not to be expected.
Glede na indikacijo in širok terapevtski razpon preveliko odmerjanje ni pričakovano.
The Patient Information Card should include:
Informacijska kartica za bolnika naj vključuje:
• High blood pressure, low blood pressure
• visok krvni tlak, nizek krvni tlak
This should be performed in accordance with the educational guidance for Nyxoid.
To je treba izvesti skladno s smernicami za izobraževanje o uporabi zdravila Nyxoid.
• not responding to a loud noise or touch.
• neodzivnost na hrup ali dotik.
Nyxoid should be administered as soon as possible to avoid damage to the central nervous system or death.
Zdravilo Nyxoid je treba dati čim hitreje, da se preprečijo poškodbe centralnega živčnega sistema ali smrt.
Genotoxicity and carcinogenicity
Genotoksičnost in karcinogenost
restlessness or irritability
nemirnost ali razdražljivost
Check airways and breathing.
Preverite dihalne poti in dihanje.
Call for an ambulance.
Pokličite rešilca.
In addition, training is provided via a video and a Patient Information Card.
Poleg tega je na voljo videoposnetek za usposabljanje in kartica z informacijami za bolnika.
Nyxoid is intended for use by appropriately trained individuals.
Zdravilo Nyxoid je namenjeno za uporabo ustrezno usposobljenim posameznikom.
Always tell your friends and family that you carry Nyxoid with you.
Svojim prijateljem in družinskim članom vedno povejte, da imate zdravilo Nyxoid pri sebi.
Pharmacotherapeutic group: Antidotes, ATC code: V03AB15
Farmakoterapevtska skupina: antidoti; oznaka ATC: V03AB15
Monitoring of the patient for a response
Spremljanje odziva bolnika na zdravilo
Like all medicines, this medicine can cause side effects although not everyone gets them.
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
Instructing patients / users on the proper use of Nyxoid
Svetovanje bolnikom/uporabnikom glede pravilne uporabe zdravila Nyxoid
Frequency categories are assigned to those adverse reactions considered to be at least possibly causally related to naloxone and are defined as very common: (≥ 1/10); common: (≥ 1/100, < 1/10); uncommon: (≥ 1/1,000, < 1/100); rare: (≥ 1/10,000, < 1/1,000) very rare: (< 1/10,000); not known
Kategorije pogostnosti so dodeljene tistim neželenim učinkom, za katere obstaja vsaj možna vzročna povezava z naloksonom, in so razvrščeni kot zelo pogosti: (≥ 1/10); pogosti: (≥ 1/100 do < 1/10); občasni: (≥ 1/1.000 do < 1/100); redki: (≥ 1/10.000 do < 1/1.000) zelo redki: (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Naloxone has not been shown to produce tolerance or cause physical or mental dependence.
Ni dokazano, da bi nalokson povzročal toleranco ali telesno ali psihično odvisnost.
Immune system disorders Very rare:
Bolezni imunskega sistema Zelo redki:
Emergency services may administer further doses according to local guidelines.
Nujna pomoč lahko bolniku da dodatne odmerke v skladu z lokalnimi smernicami.
Frequency, type and severity of adverse reactions in adolescents are expected to be the same as in adults.
Pri mladostnikih so pričakovane enaka pogostost, vrsta in resnost neželenih učinkov kot pri odraslih.
This can be done while the patient is in the recovery position.
To lahko storite, ko je bolnik v stabilnem bočnem položaju.
Be aware - even if they wake up, they may become unconscious again, and stop breathing.
Vendar upoštevajte, da tudi če se bolnik prebudi, lahko znova izgubi zavest in preneha dihati.
• Increased skin sensitivity
• prekomerna občutljivost kože
If you are allergic to naloxone or any of the other ingredients of this medicine (listed in section 6).
Če ste alergični na nalokson ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
• Allergic reactions such as swelling of the face, mouth, lips or throat, allergic shock
• alergijske reakcije, kot je otekanje obraza, ust, ustnic ali grla, alergijski šok
Acute withdrawal symptoms occur uncommonly (may affect up to 1 in 100 people).
Simptomi akutne odtegnitve se pojavijo občasno (pojavijo se lahko pri največ 1 od 100 oseb).
If the patient responds to the first administration but then relapses again into respiratory depression, the second dose should be administered immediately.
Če se bolnik odzove na prvo uporabo, nato pa se pri njem znova ponovi respiratorna depresija, mu je treba drugi odmerek dati takoj.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before receiving a supply of this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden prejmete zalogo tega zdravila.
Adults and adolescents aged 14 years and over
Odrasli in mladostniki, stari 14 let in več
There are no adequate data from the use of naloxone in pregnant women.
Na voljo ni ustreznih podatkov o uporabi naloksona pri nosečnicah.
Behavioural changes including violent behaviour, nervousness and excitement may also be observed.
Morda bo možno opaziti tudi vedenjske spremembe, vključno z agresivnim vedenjem, živčnostjo in vznemirjenostjo.
• Information on how to manage and monitor the patient until the emergency medical assistance arrives
• informacijo o tem, kako obravnavati in opazovati bolnika, dokler ne pridejo reševalci
Naloxone did not affect development or behaviour of surviving pups.
Nalokson ni vplival na razvoj ali vedenje preživelih mladičev.
For overdose of opioids (such as heroin)
Za prekomerne odmerke opioidov (npr. heroina).
Prior to launch of Nyxoid in each Member State the Marketing Authorisation Holder must agree about the content and format of the educational materials, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.
Pred začetkom trženja zdravila Nyxoid se mora imetnik dovoljenja za promet z zdravilom s pristojnim nacionalnim organom v vsaki državi članici dogovoriti o vsebini in obliki izobraževalnega programa, vključno s komunikacijskimi mediji, načinom razdeljevanja in drugimi vidiki programa.
Signs of overdose include:
Znaki prekomernega odmerjanja vključujejo:
• Emphasis on the need to make an immediate emergency call for an ambulance
• poudarek na tem, da je treba takoj poklicati reševalce
What you need to know before you receive Nyxoid Do not use Nyxoid
Kaj morate vedeti, preden boste prejeli zdravilo Nyxoid Ne uporabljajte zdravila Nyxoid
Nyxoid will be supplied to you only after you or your carer have been taught how to use it.
Zdravilo Nyxoid boste prejeli šele, ko se ga boste vi ali vaš negovalec naučili uporabljati.
No clinical data on effects of naloxone on fertility are available, however data from rat studies (see section 5.3) indicate no effects.
Na voljo ni nobenih kliničnih podatkov o učinkih naloksona na plodnost, vendar podatki iz študij pri podganah (glejte poglavje 5.3) ne kažejo nobenih učinkov.
If this happens, a second dose can be given immediately.
V tem primeru mu lahko takoj daste drugi odmerek.
Nyxoid may not fully reverse breathing problems.
Zdravilo Nyxoid morda ne bo popolnoma odpravilo težav z dihanjem.
The safety and efficacy of Nyxoid in children below 14 years has not been established.
Varnost in učinkovitost zdravila Nyxoid pri otrocih, starih manj kot 14 let, še nista bili dokazani.
Overall, the weight of evidence indicates that naloxone poses minimal, if any, risk for human genotoxicity and carcinogenicity.
Trenutni dokazi kažejo, da nalokson predstavlja minimalna tveganja, če sploh, za genotoksičnost in karcinogenost pri ljudeh.
• Awareness of possible important risks such as opioid withdrawal symptoms and recurrence of respiratory depression
• zavedanje možnih pomembnih tveganj, kot so odtegnitveni simptomi pri opioidu in ponovni pojav respiratorne depresije
Place the patient into the recovery position on their side with mouth open pointing towards the ground and stay with the patient until the emergency services arrive.
Bolnika namestite v stabilen bočni položaj, tako da ima odprta usta, ki so obrnjena proti tlom, in z bolnikom ostanite, dokler ne prispe nujna pomoč.
Adverse cardiovascular effects have occurred more frequently in postoperative patients with a pre-existing cardiovascular disease or in those receiving other medicines that produce similar adverse cardiovascular effects.
O neželenih srčno-žilnih učinkih so pogosteje poročali pri pooperativnih bolnikih z obstoječo srčno-žilno boleznijo ali pri bolnikih, ki prejemajo druga zdravila s podobnimi neželenimi srčno-žilnimi učinki.
The secondary packaging (actuator) is comprised of polypropylene and stainless steel.
Sekundarna ovojnina (sprožilnik) je iz polipropilena in nerjavečega jekla.
Watch for an improvement in the patient's breathing level, alertness and response to noise and touch.
Opazujte, ali se bodo pri bolniku izboljšale dihalne funkcije, budnost ter odzivnost na hrup in dotik.
• If you are physically dependent on opioids or if you have received high doses of opioids (for example heroin, methadone, fentanyl, oxycodone, buprenorphine or morphine).
• Če ste fizično odvisni od opioidov ali če ste prejeli visoke odmerke opioidov (na primer heroina, metadona, fentanila, oksikodona, buprenorfina ali morfija).
Patients who respond satisfactorily to Nyxoid must be closely monitored.
Bolnike, pri katerih je prisoten zadovoljiv odziv na zdravilo Nyxoid, je treba skrbno spremljati.
If you are at risk of an opioid overdose you should always carry your Nyxoid with you.
Če pri vas obstaja tveganje za prekomerni odmerek opioida, morate imeti zdravilo Nyxoid vedno pri sebi.
Symptoms can include:
Pojavijo se lahko naslednji simptomi:
If the patient does not respond to two doses, further doses may be given (if available).
Če pri bolniku po dveh odmerkih ne opazite odziva, mu lahko daste dodatne odmerke (če jih imate).
Opioid withdrawal syndrome
Opioidni odtegnitveni sindrom
Nyxoid should not be used during pregnancy unless the clinical condition of the woman requires treatment with naloxone.
Zdravila Nyxoid se ne sme uporabljati v nosečnosti, razen če zdravljenje z naloksonom zahteva klinično stanje ženske.
Other medicines and Nyxoid
Druga zdravila in zdravilo Nyxoid
What Nyxoid is and what it is used for
Kaj je zdravilo Nyxoid in za kaj ga uporabljamo
When administering naloxone to patients who have received buprenorphine as an analgesic, complete analgesia may be restored.
Pri dajanju naloksona bolnikom, ki so kot analgetik prejeli buprenorfin, je mogoče znova vzpostaviti popolno analgezijo.
Naloxone, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors.
Nalokson, polsintetični derivat morfina (N-alil-nor-oksimorfon), je specifični opioidni antagonist, ki kompetitivno deluje na opioidne receptorje.
The appropriate maximum dose of Nyxoid is situation specific.
Največji ustrezen odmerek zdravila Nyxoid je odvisen od posamezne situacije.
You may get strong withdrawal symptoms with this medicine (see later in section 4 of this leaflet under ‘Conditions to look out for')
Pri tem zdravilu se lahko pojavijo hudi simptomi odtegnitve (glejte poglavje 4 »Stanja, na katera morate biti pozorni« v teh navodilih za uporabo).